What is GLP-1 Derived From? Origins, Function & Biomarkers

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1, or glucagon-like peptide-1, is a hormone naturally produced by intestinal L-cells in response to nutrient intake, particularly glucose and fats. This endogenous hormone also appears in brain regions including the nucleus tractus solitarius, where it regulates satiety and glucose homeostasis. Understanding GLP-1's origins and dual mechanisms is essential before considering any treatment approach.

For patients exploring GLP-1 therapies, knowing how this hormone works in your body lays the foundation for informed decisions. PlexusDx emphasizes precision wellness by connecting GLP-1 mechanism knowledge with individual genetic context, supporting conversations with your healthcare provider about whether and how GLP-1-based treatment might align with your metabolic profile.

The Biological Origins of GLP-1: Where It's Made

GLP-1 is synthesized from the proglucagon gene, which encodes a large precursor protein processed differently across tissues. In the small intestine, L-cells—specialized enteroendocrine cells concentrated in the ileum and colon—cleave this precursor to release GLP-1. The hormone is secreted in response to oral nutrient intake, particularly carbohydrates and fats.

The brainstem, particularly the nucleus tractus solitarius and hypothalamus, also produces GLP-1 via preproglucagon neurons. This central production influences hunger signaling, glucose sensing, and autonomic responses. The dual intestinal-neural origin means GLP-1 acts both as a peripheral hormone and a central neurotransmitter, creating coordinated metabolic control.

Mechanisms of Action: How GLP-1 Regulates Metabolism and Appetite

GLP-1 binds to GLP-1 receptors (GLP1R) on pancreatic beta cells, promoting glucose-dependent insulin secretion. It also inhibits glucagon release, suppresses hepatic glucose production, and slows gastric emptying—collectively reducing postprandial glucose spikes. These effects depend on circulating glucose levels, meaning GLP-1 primarily acts when blood sugar is elevated.

GLP-1 Action	Primary Effect	Tissue Target
Insulin stimulation	Increases beta-cell insulin secretion glucose-dependently	Pancreatic beta cells
Glucagon suppression	Reduces hepatic glucose output	Pancreatic alpha cells
Gastric slowing	Delays nutrient absorption and meal progression	Stomach smooth muscle
Satiety signaling	Promotes fullness and reduces hunger drive	Brainstem, hypothalamus
Incretin effect	Accounts for 50-70% of postprandial insulin response	Pancreas and GI tract

GLP-1 Receptor Genetics and Individual Response Variation

The GLP1R gene contains genetic variants that may influence how efficiently your cells respond to GLP-1 signaling. The rs6923761 variant in GLP1R, for example, shows associations with metabolic traits and potential differential response patterns to GLP-1 therapies in some populations. Genetic predisposition doesn't determine outcome but may provide context for personalized dosing conversations.

PlexusDx's Precision Peptide Genetic Test evaluates variants like GLP1R rs6923761 alongside other peptide pathway markers (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) to reveal individual predispositions. These insights may help your provider tailor dosing strategy or formulation choice, supporting a more informed discussion about whether compounded semaglutide, tirzepatide, or alternative approaches align with your genetic context.

Who Should Consider GLP-1 Therapy: Evidence, Safety, and Provider Guidance

GLP-1 therapies show clinical benefit for adults with type 2 diabetes and elevated cardiovascular risk, and for weight management in those with obesity or overweight with comorbidities. However, GLP-1 is not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe kidney disease. A qualified healthcare provider must evaluate your individual risk profile before initiating treatment.

PlexusDx compounded options (semaglutide injection, oral semaglutide, tirzepatide injection, oral tirzepatide, and combination protocols) are formulated by licensed 503A compounding pharmacies and require provider oversight. Starting conversations with your doctor about GLP-1 origins, mechanisms, and your personal metabolic and genetic context ensures decisions are evidence-based and safe. Cost ranges from $129-$369/mo depending on formulation and protocol chosen with your provider.

How PlexusDx Supports a More Personalized Approach

Understanding GLP-1's origins in intestinal L-cells and the brainstem helps contextualize why individual genetic predispositions matter. PlexusDx's Precision Peptide Genetic Test may help provide context by evaluating GLP1R and related peptide pathway variants, supporting a personalized conversation with your provider about whether and how GLP-1 treatment fits your metabolic profile.

The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways—including GLP-1R, GIPR, FTO, and MC4R variants—but does not predict exact medication response or guarantee outcomes. These insights should be interpreted with a qualified healthcare provider who can integrate genetic context, clinical history, and metabolic markers into a personalized treatment plan.

Armed with knowledge of GLP-1's biological origins and your own genetic predispositions, you can engage your provider in a more informed discussion about whether compounded GLP-1 therapies align with your goals. This precision-wellness approach bridges basic science and personalized medicine, helping ensure treatment decisions are tailored to your individual circumstances.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.